August 17, 2018
Perrigo has announced plans to separate the company's prescription pharmaceuticals (Rx) business following a strategic portfolio review. Perrigo’s board of directors says it will consider all value-enhancing options, including a possible tax-efficient separation to shareholders, a sale, or merger. Read More
Mylan has formed a strategic review committee to evaluate alternatives for its businesses following weak second-quarter performance in its North American segment. Mylan says the profile of the company has changed over the last several years from a US-centric operation to an international presence. Read More
The FDA has approved the first generic drugs to receive a competitive generic therapy designation, a pathway created by the FDA to expedite the development and review of a generic drug for products that lack competition. Apotex won the approval for several strengths of potassium chloride oral solution for treating and preventing hypokalemia (low potassium blood levels).  Read More
The US Department of Justice and the US Drug Enforcement Administration have proposed a reduction for controlled substances that may be manufactured in the US in 2019. The proposal decreases manufacturing quotas for six opioids by an average of 10% in 2019 compared to 2018 levels. Read More
Emergent BioSolutions, a specialty biopharmaceutical company and contract manufacturer, has agreed to acquire PaxVax, a company focused on specialty vaccines for existing and emerging infectious diseases, for $270 million. Emergent will acquire vaccines, vaccine candidates, manufacturing facilities, and employees from PaxVax.  Read More
Regeneron Pharmaceuticals, a biopharmaceutical company, and bluebird bio, a clinical-stage gene-therapy company, have partnered to apply their technology platforms to the discovery, development, and commercialization of immune cell therapies for cancer. Regeneron is making a $100-million equity investment in bluebird bio. Read More
Astellas Pharma has acquired Quethera, a Cambridge, UK-headquartered gene-therapy company focused on developing treatments for ocular disorders, such as glaucoma, in a deal worth up to £85 million ($108 million). Read More
Catalent has completed its previously announced acquisition of Juniper Pharmaceuticals, a specialty pharmaceutical company with contract development and manufacturing services, for $133 million. The acquisition expands Catalent’s offerings in formulation development, bioavailability solutions, and clinical-scale oral-dose manufacturing and adds to its global clinical and commercial supply network. Read More
ANI Pharmaceuticals, a specialty pharmaceutical company, has acquired WellSpring Pharma Services, an Oakville, Canada-headquartered CDMO of drug products, for $18 million. WellSpring operates out of a 100,000-square-foot site in Ontario, Canada that ANI acquired as part of the transaction. Read More
Pfizer has formed a deal with Antares Pharma, a pharmaceutical company, to develop a combination drug-device rescue pen. The rescue pen will use the Antares QuickShot auto injector and an undisclosed Pfizer drug. Read More
There will be no issue of Top Industry News on August 24 and 31. The next issue of Top Industry News will be September 7.
Top Industry News is published and distributed by the Drug, Chemical & Associated Technologies Association (DCAT). The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum. For more information, visit www.dcat.org .